On October 05, 2026, AbbVie Inc (NYSE: ABBV) announced it expects a pre-tax charge of $216 million in its third-quarter 2026 results related to acquired in-process research and development (IPR&D) and milestone expenses. This charge is anticipated to reduce both GAAP and adjusted non-GAAP diluted earnings per share by approximately $0.11, with final figures pending the completion of financial statement reviews.
- AbbVie offers a dividend yield of 2.55% with a high payout ratio of 85%, alongside a steady 3-year dividend growth rate of 5.2%. Despite the elevated payout, the GF Value™ analysis suggests the stock is modestly overvalued at current prices.
- The company’s GF Score™ stands at a solid 77 out of 100, reflecting strong profitability and moderate growth, though tempered by weaker momentum and financial strength metrics.
- Insider activity reveals net selling over the past 12 months totaling $17.7 million, while 18 premium gurus currently hold ABBV shares, evenly split between additions and trims in recent quarters, signaling balanced institutional sentiment.
AbbVie's announcement of a $216 million pre-tax charge for Q3 2026 stems from expenses tied to acquired in-process research and development (IPR&D) and milestone payments. Such charges typically arise when a biopharmaceutical company enters collaborations, licensing agreements, or acquires assets, reflecting upfront or contingent costs associated with future product pipelines. While AbbVie did not provide exact Q3 financial results pending review, it updated its adjusted diluted earnings per share guidance for 2026 to a range of $13.76 to $13.96, incorporating this charge. The third-quarter adjusted EPS is estimated between $3.73 and $3.77.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.